Table 1. Clinical characteristic of patients with p53-mutant and p53-wild-type disease (univariate analysis).
| Characteristics | Total Patients, N=145 | mtp53, N=66 (%) | wtp53, N=79 (%) | * P-value |
|---|---|---|---|---|
| Age at diagnosis (median, range) | 53.4 (14.5-75.3) | 56.1 (22.2-72.6) | 51.0 (14.5-75.3) | 0.015 |
| Age at diagnosis ≥60 years | 45 | 29 (43.9%) | 16 (20.3%) | 0.004 |
| Gender Male Female |
72 73 |
34 (47.2) 32 (43.8) |
38 (52.8) 41 (56.2) |
0.740 |
| Race White Non-White |
115 30 |
58 (50.4) 8 (26.7) |
57 (49.6) 22 (73.3) |
0.024 |
| Type of cancer Breast Colorectal Endometrial Head and Neck Lung Melanoma Ovarian Pancreatic Renal Sarcoma Other GI Other GU Others |
3 31 5 12 8 13 13 3 3 23 9 9 13 |
1 (33.3) 20 (64.5) 3 (60.0) 5 (41.7) 6 (75.0) 3 (23.1) 7 (53.9) 3 (100.0) 0 (0.0) 8 (34.8) 5 (55.6) 3 (33.3) 2 (15.4) |
2 (66.7) 11 (35.5) 2 (40.0) 7 (58.3) 2 (25.0) 10 (76.9) 6 (46.1) 0 (0.00) 3 (100.0) 15 (65.2) 4 (44.4) 6 (66.7) 11 (84.6) |
|
| Site of metastasis** Brain Liver Lung Retroperitoneum Bone Lymph node Soft tissue Peritoneal Adrenal Ovary Skin |
17 79 103 34 51 110 30 48 15 19 16 |
8 (12.1) 45 (69.2) 49(75.4) 20 (30.8) 22 (33.9) 51 (78.5) 10 (15.4) 24 (36.9) 7 (10.8) 9 (28.1) 4 (6.2) |
9 (11.4) 34 (43.0) 54(68.4) 14(17.7) 29 (36.7) 59 (74.7) 20 (25.3) 24 (30.4) 8 (10.1) 10 (25.0) 12 (15.2) |
1.000 0.002 0.458 0.078 0.730 0.694 0.156 0.478 1.000 0.794 0.112 |
| Median time from diagnosis to metastases (months) | 8.9 (0 – 361.7) | 7.6 (0 – 361.7) | 9.9 (0 – 235.2) | 0.536 |
| Time from diagnosis to metastases >2 years | 32 (22) | 15 (22.7) | 17 (21.5) | 1.000 |
| Median number of phase 1 therapies (range) | 1 (0 – 4) | 1 (0 – 4) | 1 (0 – 4) | 1.000 |
| Median number of prior cancer therapies | 3 (0 – 12) | 3.5 (0 – 10) | 3 ( (0 – 12) | 0.080 |
| Median number of metastases (range)** | 3 (0 – 9) | 4 (0 – 9) | 3 ( 0 – 8) | 0.080 |
*
P-values are from Fisher's exact test or Kruskal-Wallis test, as appropriate.
**
Patients may have multiple sites of metastasis and some patients may have unavailable data on their sites of metastasis.
The P-value in each row is computed for testing the association of each metastasis site and p53 mutation.